Evidence map›Paper›PMID 41868885›Full record

ArticleCancer communications (London, England)2026

TOPK Suppresses the CD8

Nianke Zang, Jinfeng Gan, Ye Chen, Zheng Huang, Chichu Xie, Junlong Dang, Changyuan Huang, Linjie Yang, Xuelian Chen, Guangli Rong and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026
    Review
  2. The role of IRF5 as an immune regulator.Biochemical Society transactions · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nianke ZangClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Jinfeng GanGuangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, P. R. China.
Ye ChenDepartment of Immunology, School of Cell and Gene Therapy, Songjiang Institute and Songjiang Hospital Affiliated to the Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
Zheng HuangClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Chichu XieGuangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, P. R. China.
Junlong DangDepartment of Immunology, School of Cell and Gene Therapy, Songjiang Institute and Songjiang Hospital Affiliated to the Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
Changyuan HuangClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Linjie YangClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Xuelian ChenClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Guangli RongClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Jianbo SunClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Yiming ShaoClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Julie WangClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Guangying QiGuangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, P. R. China.
Yu LiuClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
Song Guo ZhengClinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CD8-Positive T-LymphocytesInterferon Regulatory FactorsMelanomaAnimalsCell Line, TumorFemaleHumansLymphocytes, Tumor-InfiltratingMiceMitogen-Activated Protein Kinase KinasesTumor MicroenvironmentInterferon Regulatory FactorsIrf5 protein, mouseMitogen-Activated Protein Kinase KinasesPDZ-binding kinase

Identifiers

PMID41868885
PMCPMC13003159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.